{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T08:46:33Z","timestamp":1789461993916,"version":"build-2803163510"},"reference-count":80,"publisher":"American College of Physicians","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.acpjournals.org\/journal\/aim\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Intern Med"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.7326\/annals-25-05468","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T21:00:36Z","timestamp":1782766836000},"page":"1328-1337","source":"Crossref","is-referenced-by-count":2,"title":["Leveraging Real-World Evidence to Inform Regulatory, Clinical, and Coverage Decisions Related to Glucagon-like Peptide-1\u2013Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop"],"prefix":"10.7326","volume":"179","author":[{"given":"David","family":"Arterburn","sequence":"first","affiliation":[{"name":"Kaiser Permanente Washington Health Research Institute, Seattle, Washington (D.A.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3286-9371","authenticated-orcid":false,"given":"Lesley H.","family":"Curtis","sequence":"additional","affiliation":[{"name":"Duke University School of Medicine, Durham, North Carolina (L.H.C., D.D., A.S.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5160-0810","authenticated-orcid":false,"given":"Sengwee","family":"Toh","sequence":"additional","affiliation":[{"name":"Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts (S.T., D.R.W.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie C.","family":"Bradley","sequence":"additional","affiliation":[{"name":"U.S. Food and Drug Administration, Washington, DC (M.C.B.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"D\u2019Alessio","sequence":"additional","affiliation":[{"name":"Duke University School of Medicine, Durham, North Carolina (L.H.C., D.D., A.S.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5626-0589","authenticated-orcid":false,"given":"Noelia","family":"Duchovny","sequence":"additional","affiliation":[{"name":"Congressional Budget Office, Washington, DC (N.D.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8288-0029","authenticated-orcid":false,"given":"David","family":"Hines","sequence":"additional","affiliation":[{"name":"Metro Nashville Public Schools, Nashville, Tennessee (D.H.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8548-1728","authenticated-orcid":false,"given":"Kimberly","family":"Narain","sequence":"additional","affiliation":[{"name":"University of California, Los Angeles, Los Angeles, California (K.N.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Parekh","sequence":"additional","affiliation":[{"name":"University of Michigan School of Public Health, Ann Arbor, Michigan (A.P.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asheley","family":"Skinner","sequence":"additional","affiliation":[{"name":"Duke University School of Medicine, Durham, North Carolina (L.H.C., D.D., A.S.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina C.","family":"Wee","sequence":"additional","affiliation":[{"name":"Annals of Internal Medicine and American College of Physicians, Philadelphia, Pennsylvania (C.C.W.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4203-9010","authenticated-orcid":false,"given":"John B.","family":"Wong","sequence":"additional","affiliation":[{"name":"Tufts University School of Medicine, Boston, Massachusetts (J.B.W.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8574-4572","authenticated-orcid":false,"given":"Davene R.","family":"Wright","sequence":"additional","affiliation":[{"name":"Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts (S.T., D.R.W.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavroula K.","family":"Osganian","sequence":"additional","affiliation":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland (S.K.O., C.H.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2355-1177","authenticated-orcid":false,"given":"Craig","family":"Hales","sequence":"additional","affiliation":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland (S.K.O., C.H.)."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4285","reference":[{"key":"r1-ANNALS2505468","doi-asserted-by":"publisher","DOI":"10.7326\/AITC202405210"},{"key":"r2-ANNALS2505468","doi-asserted-by":"publisher","DOI":"10.7326\/ANNALS-24-02933"},{"key":"r3-ANNALS2505468","doi-asserted-by":"publisher","DOI":"10.7326\/ANNALS-24-03609"},{"key":"r4-ANNALS2505468","doi-asserted-by":"crossref","unstructured":"Bozick R, Donofry SD, Ranca\u00f1o KM.\n                      New Weight Loss Drugs: GLP-1 Agonist Use and Side Effects in the United States. RAND Corporation; 6 August 2025. Accessed at https:\/\/www.rand.org\/pubs\/research_reports\/RRA4153-1.html on 4 December 2025.","DOI":"10.7249\/rhq-13-01-03"},{"key":"r5-ANNALS2505468","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.13665"},{"key":"r6-ANNALS2505468","unstructured":"U.S. Food and Drug Administration\n                      . FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Accessed at https:\/\/www.fda.gov\/drugs\/fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-public-dashboard on 4 December 2025."},{"key":"r7-ANNALS2505468","doi-asserted-by":"publisher","DOI":"10.7326\/ANNALS-26-00202"},{"key":"r8-ANNALS2505468","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00387"},{"key":"r9-ANNALS2505468","doi-asserted-by":"publisher","DOI":"10.1210\/edrv.20.6.0385"},{"key":"r10-ANNALS2505468","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2013.04.008"},{"key":"r11-ANNALS2505468","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-37-5-826"},{"key":"r12-ANNALS2505468","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116186"},{"key":"r13-ANNALS2505468","doi-asserted-by":"publisher","DOI":"10.1007\/BF00401145"},{"key":"r14-ANNALS2505468","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.80.3.7883856"},{"key":"r15-ANNALS2505468","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69705-5"},{"key":"r16-ANNALS2505468","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnaa032"},{"key":"r17-ANNALS2505468","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13358"},{"key":"r18-ANNALS2505468","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac276"},{"key":"r19-ANNALS2505468","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2023.07.010"},{"key":"r20-ANNALS2505468","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/hpaf072"},{"key":"r21-ANNALS2505468","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-023-00849-3"},{"key":"r22-ANNALS2505468","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307563"},{"key":"r23-ANNALS2505468","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae296"},{"key":"r24-ANNALS2505468","doi-asserted-by":"publisher","DOI":"10.1172\/JCI186425"},{"key":"r25-ANNALS2505468","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2404881"},{"key":"r26-ANNALS2505468","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2505669"},{"key":"r27-ANNALS2505468","unstructured":"U.S. Food and Drug Administration\n                      . 21st Century Cures Act. Accessed at https:\/\/www.fda.gov\/regulatory-information\/selected-amendments-fdc-act\/21st-century-cures-act on 4 December 2025."},{"key":"r28-ANNALS2505468","unstructured":"U.S. Food and Drug Administration\n                      . Framework for FDA\u2019s Real-World Evidence Program. December 2018. Accessed at https:\/\/www.fda.gov\/media\/120060\/download?attachment on 4 December 2025."},{"key":"r29-ANNALS2505468","unstructured":"U.S. Food and Drug Administration\n                      . Real-World Evidence. Accessed at https:\/\/www.fda.gov\/science-research\/science-and-research-special-topics\/real-world-evidence on 4 December 2025."},{"key":"r30-ANNALS2505468","unstructured":"U.S. Food and Drug Administration\n                      . FDA approves new use of transplant drug based on real-world evidence. 16 July 2021. Accessed at https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-new-use-transplant-drug-based-real-world-evidence on 4 December 2025."},{"key":"r31-ANNALS2505468","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00676-0"},{"key":"r32-ANNALS2505468","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2979"},{"key":"r33-ANNALS2505468","unstructured":"Intentional self-harm following glucagon-like peptide-1 receptor agonists (GLP-1 RA) use in patients with diabetes: an inverse probability of treatment weighting analysis. Accessed at https:\/\/www.sentinelinitiative.org\/studies\/drugs\/individual-drug-analyses\/intentional-self-harm-following-glucagon-peptide-1-receptor on 4 December 2025."},{"key":"r34-ANNALS2505468","unstructured":"Intentional self-harm following glucagon-like peptide-1 receptor agonists (GLP-1 RA) use in patients with obesity: a descriptive analysis. Accessed at https:\/\/www.sentinelinitiative.org\/studies\/drugs\/individual-drug-analyses\/intentional-self-harm-following-glucagon-peptide-1-0 on 4 December 2025."},{"key":"r35-ANNALS2505468","unstructured":"U.S. Preventive Services Task Force\n                      . About the USPSTF. Accessed at https:\/\/www.uspreventiveservicestaskforce.org\/uspstf\/about-uspstf on 22 October 2025."},{"key":"r36-ANNALS2505468","unstructured":"American Diabetes Association\n                      . Who We Are. Accessed at https:\/\/diabetes.org\/about-us on 22 October 2025."},{"key":"r37-ANNALS2505468","unstructured":"American Academy of Pediatrics website. Accessed at https:\/\/www.aap.org\/en on 22 October 2025."},{"key":"r38-ANNALS2505468","unstructured":"U.S. Preventive Services Task Force\n                      . Task Force at a Glance. Accessed at https:\/\/www.uspreventiveservicestaskforce.org\/uspstf\/about-uspstf\/task-force-at-a-glance on 22 October 2025."},{"key":"r39-ANNALS2505468","unstructured":"U.S. Preventive Services Task Force\n                      . Procedure Manual. Accessed at https:\/\/www.uspreventiveservicestaskforce.org\/uspstf\/about-uspstf\/methods-and-processes\/procedure-manual on 7 July 2025."},{"key":"r40-ANNALS2505468","unstructured":"U.S. Preventive Services Task Force\n                      . Grade Definitions. Accessed at https:\/\/www.uspreventiveservicestaskforce.org\/uspstf\/about-uspstf\/methods-and-processes\/grade-definitions on 22 October 2025."},{"key":"r41-ANNALS2505468","unstructured":"U.S. Preventive Services Task Force\n                      . Procedure Manual Section 3. Topic Work Plan Development. Accessed at https:\/\/www.uspreventiveservicestaskforce.org\/uspstf\/about-uspstf\/methods-and-processes\/procedure-manual\/procedure-manual-section-3-topic-work-plan-development on 22 October 2025."},{"key":"r42-ANNALS2505468","unstructured":"U.S. Preventive Services Task Force\n                      . Procedure Manual Section 4. Evidence Review Development. Accessed at https:\/\/www.uspreventiveservicestaskforce.org\/uspstf\/about-uspstf\/methods-and-processes\/procedure-manual\/procedure-manual-section-4-evidence-review-development on 22 October 2025."},{"key":"r43-ANNALS2505468","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.13022"},{"key":"r44-ANNALS2505468","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.7777"},{"key":"r45-ANNALS2505468","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.3267"},{"key":"r46-ANNALS2505468","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-S001"},{"key":"r47-ANNALS2505468","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-S008"},{"key":"r48-ANNALS2505468","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2022-060640"},{"key":"r49-ANNALS2505468","doi-asserted-by":"publisher","DOI":"10.1056\/evidoa2200014"},{"key":"r50-ANNALS2505468","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2208601"},{"key":"r51-ANNALS2505468","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2016.185"},{"key":"r52-ANNALS2505468","doi-asserted-by":"publisher","DOI":"10.1001\/jama.293.23.2873"},{"key":"r53-ANNALS2505468","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1916038"},{"key":"r54-ANNALS2505468","unstructured":"Desilver D\n                      . What the Data Says About Medicaid. Pew Research Center; 24 June 2025. Accessed at https:\/\/www.pewresearch.org\/short-reads\/2025\/06\/24\/what-the-data-says-about-medicaid\/#how-many-people-have-medicaid-coverage on 2 November 2025."},{"key":"r55-ANNALS2505468","doi-asserted-by":"publisher","DOI":"10.2147\/JMDH.S419245"},{"key":"r56-ANNALS2505468","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2016.04.016"},{"key":"r57-ANNALS2505468","unstructured":"Hoagland GW, Lovegrove M, Parekh A, et al\n                      . Expanding Access to Obesity Treatments for Older Adults. Bipartisan Policy Center; February 2022. Accessed at https:\/\/bipartisanpolicy.org\/wp-content\/uploads\/2022\/02\/BPC_ExpandingAccessToObesityFinal.pdf on 29 August 2025."},{"key":"r58-ANNALS2505468","unstructured":"Congressional Budget Office\n                      . How Would Authorizing Medicare to Cover Anti-Obesity Medications Affect the Federal Budget? October 2024. Accessed at https:\/\/www.cbo.gov\/publication\/60816 on 4 December 2025."},{"key":"r59-ANNALS2505468","unstructured":"Department of Health and Human Services\n                      . Medicare and Medicaid Programs; Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly. Accessed at https:\/\/www.govinfo.gov\/content\/pkg\/FR-2024-12-10\/pdf\/2024-27939.pdf on 4 December 2025."},{"key":"r60-ANNALS2505468","unstructured":"The White House\n                      . Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. 12 May 2025. Accessed at https:\/\/www.whitehouse.gov\/presidential-actions\/2025\/05\/delivering-most-favored-nation-prescription-drug-pricing-to-american-patients on 4 December 2025."},{"key":"r61-ANNALS2505468","unstructured":"The White House\n                      . Fact Sheet: President Donald J. Trump Announces Major Developments in Bringing Most-Favored-Nation Pricing to American Patients. 6 November 2025. Accessed at https:\/\/www.whitehouse.gov\/fact-sheets\/2025\/11\/fact-sheet-president-donald-j-trump-announces-major-developments-in-bringing-most-favored-nation-pricing-to-american-patients on 11 December 2025."},{"key":"r62-ANNALS2505468","unstructured":"TRICARE\n                      . Does TRICARE cover Wegovy, Ozempic, and Mounjaro? Accessed at https:\/\/tricare.mil\/FAQs\/Pharmacy\/PharmProg_Wegovy on 4 December 2025."},{"key":"r63-ANNALS2505468","unstructured":"Moss K\n                      . Feds with Benefits: Does FEHB cover weight loss medications? Federal News Network; 11 September 2024. Accessed at https:\/\/federalnewsnetwork.com\/feds-with-benefits\/2024\/09\/feds-with-benefits-does-fehb-cover-weight-loss-medications on 4 December 2025."},{"key":"r64-ANNALS2505468","unstructured":"Ingmire B\n                      . GLP-1 Weight Loss Drugs: Coverage Under Medicaid and Other Health Plans. MultiState; 17 March 2025. Accessed at https:\/\/www.multistate.us\/insider\/2025\/3\/17\/glp-1-weight-loss-drugs-coverage-under-medicaid-and-other-health-plans on 4 December 2025."},{"key":"r65-ANNALS2505468","unstructured":"Williams E, Rudowithz R, Bell C\n                      . Medicaid Coverage of and Spending on GLP-1s. Accessed at https:\/\/www.kff.org\/medicaid\/medicaid-coverage-of-and-spending-on-glp-1s on 4 December 2025."},{"key":"r66-ANNALS2505468","doi-asserted-by":"crossref","unstructured":"Pearson SD, Whaley CM, Emond SK\n                      . Affordable Access to GLP-1 Obesity Medications: Strategies to Guide Market Action and Policy Solutions. Institute for Clinical and Economic Review; 9 April 2025. Accessed at https:\/\/icer.org\/wp-content\/uploads\/2025\/04\/Affordable-Access-to-GLP-1-Obesity-Medications-_-ICER-White-Paper-_-04.09.2025.pdf on 4 December 2025.","DOI":"10.57264\/cer-2025-0083"},{"key":"r67-ANNALS2505468","doi-asserted-by":"publisher","DOI":"10.7326\/ANNALS-24-01317"},{"key":"r68-ANNALS2505468","unstructured":"Hunzinger G, Skoog D, Sclafani P, et al\n                      . No let up in sight. Medical cost trend set to grow at 8.5%. Is your playbook ready? Behind the Numbers 2026. PwC; 16 July 2025. Accessed at https:\/\/www.pwc.com\/us\/en\/industries\/health-industries\/library\/behind-the-numbers.html on 4 December 2025."},{"key":"r69-ANNALS2505468","unstructured":"Milanette T\n                      . Healthcare Volatility Wreaks Havoc on Predicting Risk and Managing Costs. Accessed at https:\/\/www.iqvia.com\/-\/media\/iqvia\/pdfs\/us\/white-paper\/2023\/iqvia-hcs-risk-article-2023.pdf on 14 April 2026."},{"key":"r70-ANNALS2505468","unstructured":"Cotter L, Rae M, McGough M, et al\n                      . Perspectives from employers on the costs and issues associated with covering GLP-1 agonists for weight loss. Peterson-KFF Health System Tracker; 22 October 2025. Accessed at https:\/\/www.healthsystemtracker.org\/brief\/perspectives-from-employers-on-the-costs-and-issues-associated-with-covering-glp-1-agonists-for-weight-loss on 14 April 2026."},{"key":"r71-ANNALS2505468","unstructured":"KFF\n                      . 2024 Employer Health Benefits Survey. 9 October 2025. Accessed at https:\/\/www.kff.org\/health-costs\/2024-employer-health-benefits-survey on 4 December 2025."},{"key":"r72-ANNALS2505468","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000006333"},{"key":"r73-ANNALS2505468","doi-asserted-by":"publisher","DOI":"10.1002\/osp4.727"},{"key":"r74-ANNALS2505468","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-023-06856-0"},{"key":"r75-ANNALS2505468","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2020.1985"},{"key":"r76-ANNALS2505468","doi-asserted-by":"publisher","DOI":"10.1111\/obr.12932"},{"key":"r77-ANNALS2505468","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2019.3732"},{"key":"r78-ANNALS2505468","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2013.1504"},{"key":"r79-ANNALS2505468","unstructured":"Atlas SJ, Kim K, Beinfeld M, et al\n                      . Medications for Obesity Management: Effectiveness and Value. Institute for Clinical and Economic Review; 31 August 2022. Accessed at https:\/\/icer.org\/wp-content\/uploads\/2022\/03\/ICER_Obesity_Evidence_Report_083122.pdf on 4 December 2025."},{"key":"r80-ANNALS2505468","unstructured":"Ward AS, Tysinger B, Nguyen P, et al\n                      . Benefits of Medicare Coverage for Weight Loss Drugs. Accessed at https:\/\/schaeffer.usc.edu\/research\/benefits-of-medicare-coverage-for-weight-loss-drugs on 4 December 2025."}],"container-title":["Annals of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.acpjournals.org\/doi\/pdf\/10.7326\/ANNALS-25-05468","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.acpjournals.org\/doi\/full-xml\/10.7326\/ANNALS-25-05468","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T21:02:29Z","timestamp":1789419749000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.acpjournals.org\/doi\/10.7326\/ANNALS-25-05468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":80,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.7326\/ANNALS-25-05468"],"URL":"https:\/\/doi.org\/10.7326\/annals-25-05468","relation":{},"ISSN":["0003-4819","1539-3704"],"issn-type":[{"value":"0003-4819","type":"print"},{"value":"1539-3704","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}